The FDA has approved Bravnetsa (lutetium Lu 177 dotatate) via the ANDA pathway as a bioequivalent treatment option for SSTR-positive GEP-NETs.

Isolated diastolic hypertension in young adults is associated with an increased risk for atherosclerotic cardiovascular disease and heart failure.

Endometriosis macrophenotypes exhibit distinct risk factor profiles and comorbidity patterns, suggesting varying disease etiologies.

IBD is not associated with increased risk for hypertensive disorders of pregnancy, but is associated with increased risk for preeclampsia.

Few women initiate systemic hormone therapy for menopausal symptoms, and the majority of patients who do discontinue treatment within the first year.

Cardiovascular outcomes do not differ significantly by sex among patients receiving tirzepatide for obesity and heart failure.

Cultural stigma and sensationalized media narratives regarding GLP-1 RAs contribute to patient drug avoidance and treatment ...

The FDA has approved Kerendia (finerenone) to reduce UACR, which is expected to slow CKD progression in adults with type 1 diabetes.

Exocrine pancreatic insufficiency is prevalent among adults with T1D and is linked to higher hemoglobin A1c and mean glucose levels.

Deep-seated systemic and implicit racial biases within health care education, clinical decision-making, and diagnostic practices continue to drive persistent disparities in patient outcomes for people ...

For adults with T2D receiving SGLT2is, risk factors for ketoacidosis include high HbA1c, previous ketoacidosis, and recent hypoglycemia.

The FDA has granted Priority Review to Alexion's BLA for efzimfotase alfa, a biweekly enzyme replacement therapy for hypophosphatasia.